The burden of disease of Chinese females cervical cancer from 1990 to 2019_Chinese Journal of Evidence-Based Medicine

Authors：

MENG Linghao ¹ , XU Qiuyan ² , LI Ke ³ , XU Wenli ⁴ ,  HUANG Lei ²

1. West China School of Medicine and West China Hospital, Sichuan University, Chengdu 610041, P.R.China;
2. West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, P.R.China;
3. Department of Chronic Disease Prevention and Control, Guangzhou Center for Disease Control and Prevention, Guangzhou 510440, P.R.China;
4. China Birth Defects Monitoring Center, West China Second Hospital, Sichuan University, Chengdu 610041, P.R.China;

Corresponding?author：

HUANG Lei, Email: hlst0610@163.com

Keywords：

Cervical cancer; Incidence; Mortality; Burden of disease

DOI：

10.7507/1672-2531.202101091

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To analyze the trends of incidence, mortality, and burden of disease of cervical cancer in Chinese females from 1990 to 2019.Methods The global burden of disease database (GBD) and China health statistics yearbook data was used to analyze the incidence, standardized incidence, mortality, standardized mortality, urban and rural mortality, and burden of cervical cancer among Chinese females using Excel, SPSS 21.0 and Joinpoint Regression Program 4.8.0.1.Results The standardized incidence of cervical cancer among Chinese females increased from 9.21/100 000 in 1990 to 12.06/100 000 in 2019, and the standardized mortality decreased from 8.40/100 000 to 7.36/100 000. The standardized mortality of cervical cancer in 2018 decreased when compared with 2015 in both urban and rural areas. Changes in age-group incidence and mortality indicated that there was a younger trend in cervical cancer. The disease burden indicators (DALY, YLL, and YLD) were increased from 86.49, 84.01, and 1.52 ten thousand person/years to 162.22, 157.40, and 4.83 ten thousand person/years, in which the YLD increased the most (217.76%). The APC of DALY, YLL and YLD were 2.39%, 2.56% and 4.25%, respectively. The proportion of cervical cancer disease burden in female cancer increased in 2019 compared with 1990. And DALY, YLL and YLD increased in the age group of 40 or over, in which DALY of the age group 50-54 increased 167.15%.Conclusions The situation of cervical cancer is not optimistic in China. Although the mortality of cervical cancer has decreased in recent years, the number of cases and mortalities is still increasing. Not only the burden of disease is continuously increasing, there is also a younger trend in cervical cancer. Active preventive measures should be taken to reduce the burden of cervical cancer.

Citation： MENG Linghao, XU Qiuyan, LI Ke, XU Wenli, HUANG Lei. The burden of disease of Chinese females cervical cancer from 1990 to 2019. Chinese Journal of Evidence-Based Medicine, 2021, 21(6): 648-653. doi: 10.7507/1672-2531.202101091 Copy

1.	Vu M, Yu J, Awolude OA, et al. Cervical cancer worldwide. Curr Probl Cancer, 2018, 42(5): 457-465.
2.	Li K, Li Q, Song L, et al. The distribution and prevalence of human papillomavirus in women in mainland China. Cancer, 2019, 125(7): 1030-1037.
3.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
4.	Lowy DR, Solomon D, Hildesheim A, et al. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer, 2008, 113(7 Suppl): 1980-1993.
5.	Zeng Z, Yang H, Li Z, et al. Prevalence and genotype distribution of HPV infection in China: analysis of 51, 345 HPV genotyping results from China's largest CAP certified laboratory. J Cancer, 2016, 7(9): 1037-1043.
6.	Li K, Yin R, Wang D, et al. Human papillomavirus subtypes distribution among 2309 cervical cancer patients in West China. Oncotarget, 2017, 8(17): 28502-28509.
7.	丁賢彬, 呂曉燕, 毛德強, 等. 2010-2017 年重慶市宮頸癌疾病負擔變化趨勢分析. 中國腫瘤, 2019, 28(9): 657-662.
8.	董惠玲, 楊瑞貞, 趙飛燕, 等. 2012 年山東省主要惡性腫瘤疾病負擔評價. 中國腫瘤, 2016, 25(1): 20-24.
9.	GBD. Global health data exchange. Available at: http://ghdx.healthdata.org/gbd-results-tool.
10.	GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet, 2020, 396(10258): 1204-1222.
11.	GBD 2013 DALYs and HALE Collaborators, Murray CJ, Barber RM, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet, 2015, 386(10009): 2145-2191.
12.	Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, et al. The Global Burden of Cancer 2013. JAMA Oncol, 2015, 1(4): 505-527.
13.	Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2163-2196.
14.	Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet, 2016, 387(10015): 251-272.
15.	GBD 2013 Risk Factors Collaborators, Forouzanfar MH, Alexander L, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet, 2015, 386(10010): 2287-2323.
16.	齊金蕾, 王黎君, 周脈耕, 等. 1990-2013 年中國男性前列腺癌疾病負擔分析. 中華流行病學雜志, 2016, 37(6): 778-782.
17.	Shrestha AD, Neupane D, Vedsted P, et al. Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pac J Cancer Prev, 2018, 19(2): 319-324.
18.	鄭詩丹, 王曉平. 宮頸癌發病率與患者生活因素的相關性研究. 齊齊哈爾醫學院學報, 2016, 37(5): 572-573.
19.	Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 189(1): 12-19.
20.	Canfell K, Kim JJ, Brisson M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, 2020, 395(10224): 591-603.
21.	Zhao F, Qiao Y. Cervical cancer prevention in China: a key to cancer control. Lancet, 2019, 393(10175): 969-970.
22.	Hancock G, Hellner K, Dorrell L. Therapeutic HPV vaccines. Best Pract Res Clin Obstet Gynaecol, 2018, 47: 59-72.
23.	Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol, 2013, 10(7): 400-410.
24.	Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States. Ann Intern Med, 2020, 172(1): 22-29.
25.	Sundstr?m K, Elfstr?m KM. Advances in cervical cancer prevention: Efficacy, effectiveness, elimination? PLoS Med, 2020, 17(1): e1003035.
26.	García-Perdomo HA, Osorio JC, Fernandez A, et al. The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis. Epidemiol Infect, 2019, 147: e156.
27.	WHO. Accelerating the elimination of cervical cancer as a global public health problem. Available at: https://apps.who.int/gb/ebwha/pdf_files/EB144/B144(2)-en.pdf.
28.	Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med, 2018, 7(10): 5217-5236.
29.	謝珊艷, 任鵬. 宮頸癌發病年輕化的趨勢分析與相應對策. 中醫藥管理雜志, 2018, 26(5): 10-12.
30.	任春麗. 近 20 年長春地區宮頸癌發病趨勢和臨床病例分析. 吉林: 吉林大學, 2006.
31.	Pimple SA, Mishra GA. Global strategies for cervical cancer prevention and screening. Minerva Ginecol, 2019, 71(4): 313-320.
32.	Ogilvie G, Nakisige C, Huh WK, et al. Optimizing secondary prevention of cervical cancer: Recent advances and future challenges. Int J Gynaecol Obstet, 2017, 138(Suppl 1): 15-19.

1. Vu M, Yu J, Awolude OA, et al. Cervical cancer worldwide. Curr Probl Cancer, 2018, 42(5): 457-465.
2. Li K, Li Q, Song L, et al. The distribution and prevalence of human papillomavirus in women in mainland China. Cancer, 2019, 125(7): 1030-1037.
3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
4. Lowy DR, Solomon D, Hildesheim A, et al. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer, 2008, 113(7 Suppl): 1980-1993.
5. Zeng Z, Yang H, Li Z, et al. Prevalence and genotype distribution of HPV infection in China: analysis of 51, 345 HPV genotyping results from China's largest CAP certified laboratory. J Cancer, 2016, 7(9): 1037-1043.
6. Li K, Yin R, Wang D, et al. Human papillomavirus subtypes distribution among 2309 cervical cancer patients in West China. Oncotarget, 2017, 8(17): 28502-28509.
7. 丁賢彬, 呂曉燕, 毛德強, 等. 2010-2017 年重慶市宮頸癌疾病負擔變化趨勢分析. 中國腫瘤, 2019, 28(9): 657-662.
8. 董惠玲, 楊瑞貞, 趙飛燕, 等. 2012 年山東省主要惡性腫瘤疾病負擔評價. 中國腫瘤, 2016, 25(1): 20-24.
9. GBD. Global health data exchange. Available at: http://ghdx.healthdata.org/gbd-results-tool.
10. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet, 2020, 396(10258): 1204-1222.
11. GBD 2013 DALYs and HALE Collaborators, Murray CJ, Barber RM, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet, 2015, 386(10009): 2145-2191.
12. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, et al. The Global Burden of Cancer 2013. JAMA Oncol, 2015, 1(4): 505-527.
13. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2163-2196.
14. Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet, 2016, 387(10015): 251-272.
15. GBD 2013 Risk Factors Collaborators, Forouzanfar MH, Alexander L, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet, 2015, 386(10010): 2287-2323.
16. 齊金蕾, 王黎君, 周脈耕, 等. 1990-2013 年中國男性前列腺癌疾病負擔分析. 中華流行病學雜志, 2016, 37(6): 778-782.
17. Shrestha AD, Neupane D, Vedsted P, et al. Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pac J Cancer Prev, 2018, 19(2): 319-324.
18. 鄭詩丹, 王曉平. 宮頸癌發病率與患者生活因素的相關性研究. 齊齊哈爾醫學院學報, 2016, 37(5): 572-573.
19. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 189(1): 12-19.
20. Canfell K, Kim JJ, Brisson M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, 2020, 395(10224): 591-603.
21. Zhao F, Qiao Y. Cervical cancer prevention in China: a key to cancer control. Lancet, 2019, 393(10175): 969-970.
22. Hancock G, Hellner K, Dorrell L. Therapeutic HPV vaccines. Best Pract Res Clin Obstet Gynaecol, 2018, 47: 59-72.
23. Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol, 2013, 10(7): 400-410.
24. Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States. Ann Intern Med, 2020, 172(1): 22-29.
25. Sundstr?m K, Elfstr?m KM. Advances in cervical cancer prevention: Efficacy, effectiveness, elimination? PLoS Med, 2020, 17(1): e1003035.
26. García-Perdomo HA, Osorio JC, Fernandez A, et al. The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis. Epidemiol Infect, 2019, 147: e156.
27. WHO. Accelerating the elimination of cervical cancer as a global public health problem. Available at: https://apps.who.int/gb/ebwha/pdf_files/EB144/B144(2)-en.pdf.
28. Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med, 2018, 7(10): 5217-5236.
29. 謝珊艷, 任鵬. 宮頸癌發病年輕化的趨勢分析與相應對策. 中醫藥管理雜志, 2018, 26(5): 10-12.
30. 任春麗. 近 20 年長春地區宮頸癌發病趨勢和臨床病例分析. 吉林: 吉林大學, 2006.
31. Pimple SA, Mishra GA. Global strategies for cervical cancer prevention and screening. Minerva Ginecol, 2019, 71(4): 313-320.
32. Ogilvie G, Nakisige C, Huh WK, et al. Optimizing secondary prevention of cervical cancer: Recent advances and future challenges. Int J Gynaecol Obstet, 2017, 138(Suppl 1): 15-19.

Previous Article
The incidence and risk factors of tuberculosis in Mianyang in Sichuan Province
Next Article
Efficacy of BMI on all-cause mortality in frail elderly: a dose-response meta-analysis

Chinese Journal of Evidence-Based Medicine

The burden of disease of Chinese females cervical cancer from 1990 to 2019

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content